Equities

Dynavax Technologies Corp

Dynavax Technologies Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)12.42
  • Today's Change0.06 / 0.49%
  • Shares traded902.48k
  • 1 Year change-7.86%
  • Beta1.3292
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments742624546
Total Receivables, Net45148132
Total Inventory535961
Prepaid expenses1986233
Other current assets, total------
Total current assets859917973
Property, plant & equipment, net626361
Goodwill, net2.072.012.13
Intangibles, net------
Long term investments------
Note receivable - long term------
Other long term assets743.313.40
Total assets9979861,039
LIABILITIES
Accounts payable5.253.212.60
Accrued expenses57147186
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total0.020368
Total current liabilities62150556
Total long term debt223222220
Total debt223222220
Deferred income tax------
Minority interest------
Other liabilities, total903340
Total liabilities375405817
SHAREHOLDERS EQUITY
Common stock0.130.130.12
Additional paid-in capital1,5551,5111,442
Retained earnings (accumulated deficit)(931)(924)(1217)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(2.11)(5.44)(2.27)
Total equity622581222
Total liabilities & shareholders' equity9979861,039
Total common shares outstanding130128123
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.